Clinical Trial Update: Assessment of Tolerance of Mobilizing Peripheral Hematopoietic Stem Cells by Plerixafor in Sickle Cell Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial assessing tolerance of mobilizing peripheral hematopoietic stem cells using plerixafor in patients with sickle cell disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Plerixafor (Plerixafor)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Major Sickle Cell Syndrome of Type SS or Sβ Thalassemia | Phase 1, Phase 2 | Status: COMPLETED